Givinostat

Becker Muscular Dystrophy

ItalfarmacoSmall moleculePhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 39/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Becker Muscular Dystrophy cohort.

Asset / Sponsor	Phase	Rating
(-)-Epicatechin Craig McDonald, MD	Phase 2	BB
Tadalafil Cedars-Sinai Medical Center	Phase 4	BB
CARVEDILOL Catholic University, Italy	Phase 4	BB
Ataluren PTC Therapeutics	Phase 3	BB
Lisinopril Cooperative International Neuromuscular Research Group	Phase 2/3	B

View all 19 →

Same molecule, other indications

Givinostat is also rated in:

Duchenne muscular dystrophyDormant

BB

Indicative ·

64 / 100

Hodgkins lymphomaDormant

CCC

Indicative ·

49 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

CCC

Indicative ·

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.